Market Newsdesk

Omeros to Present at the 39^th Annual J.P. Morgan Healthcare Conference

SEATTLE–(BUSINESS WIRE)–
Omeros Corporation (Nasdaq: OMER) today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 39^th Annual J.P. Morgan Healthcare Conference this week. This conference is being held as a virtual conference this year. The presentation is scheduled for Wednesday, January 13, 2021 at 10:50 a.m. EST.

The presentation will be webcast. The live and archived webcasts can be accessed on the investor relations section of the company’s website at www.omeros.com under “Events.” The archived webcast will be available for 30 days.

About Omeros Corporation

Omeros is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers. Its commercial product OMIDRIA (phenylephrine and ketorolac intraocular solution) 1%/0.3% continues to gain market share in cataract surgery. Omeros’ lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a rolling biologics license application under review by FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, atypical hemolytic uremic syndrome and COVID-19. Omeros’ MASP-3 inhibitor OMS906, which targets the complement system’s alternative pathway, recently entered the clinic, and the company’s PDE7 inhibitor OMS527 has successfully completed its Phase 1 trial. Omeros’ pipeline holds a diverse group of preclinical programs including a novel antibody-generating technology and a proprietary GPCR platform through which it controls 54 new GPCR drug targets and their corresponding compounds. One of these novel targets, GPR174, modulates a new cancer immunity axis recently discovered by Omeros, and the company is advancing small-molecule GPR174 inhibitors.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210111006026/en/

Jennifer Cook Williams

Cook Williams Communications, Inc.

Investor and Media Relations

360.668.3701

[email protected]

KEYWORDS: United States North America Washington

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health Other Health

MEDIA:

Logo

Hess Midstream LP Schedules Earnings Release Conference Call

HOUSTON–(BUSINESS WIRE)–
Hess Midstream LP (NYSE: HESM) (“Hess Midstream”) announced today that it will hold a conference call on Wednesday, January 27, 2021 at 12:00 p.m. Eastern Time to discuss its fourth quarter 2020 earnings release.

To phone into the conference call, parties in the United States should dial 866-395-9624 and enter the passcode 7380097 after 11:45 a.m. Outside the United States, parties should dial 213-660-0871 and enter the passcode 7380097. This conference call will also be accessible by webcast (audio only) on Hess Midstream’s website at www.hessmidstream.com.

A replay of the conference call will be available from January 27, 2021 through February 11, 2021, by dialing 855-859-2056 and entering the passcode 7380097. Outside the United States, parties should dial 404-537-3406 and enter the passcode 7380097.

About Hess Midstream

Hess Midstream is a fee-based, growth-oriented, midstream company that owns, operates, develops and acquires a diverse set of midstream assets to provide services to Hess and third-party customers. Hess Midstream owns oil, gas and produced water handling assets that are primarily located in the Bakken and Three Forks Shale plays in the Williston Basin area of North Dakota. More information is available at www.hessmidstream.com.

Forward Looking Statements

This press release may include forward-looking statements within the meaning of the federal securities laws. Generally, the words “anticipate,” “estimate,” “expect,” “forecast,” “guidance,” “could,” “may,” “should,” “believe,” “intend,” “project,” “plan,” “predict,” “will” and similar expressions identify forward-looking statements, which generally are not historical in nature. Forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results and current projections or expectations. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements in the filings made by Hess Midstream with the U.S. Securities and Exchange Commission, which are available to the public. Hess Midstream undertakes no obligation to, and does not intend to, update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210111006023/en/

Investor Contact:

Jennifer Gordon

(212) 536-8244

Media Contact:

Robert Young

(713) 496-6076

KEYWORDS: United States North America Texas

INDUSTRY KEYWORDS: Oil/Gas Energy

MEDIA:

Logo

CES 2021: Intel Announces Four New Processor Families

Delivering the Best Business, Education, Mobile and Gaming Computing Platforms for More Than 500 New PC Designs Coming in 2021

NEWS HIGHLIGHTS

• At its CES news conference, Intel highlighted how it is driving technology leadership with the introduction of more than 50 processors, resulting in more than 500 new designs for laptops and desktops coming to market in 2021.
• Intel launched the 11th Gen Intel^® Core™ vPro^® platform and Intel^® Evo™ vPro^® platform, delivering the highest performance and most comprehensive hardware-based security¹.
• Intel introduced the new N-series 10-nanometer Intel^® Pentium^® Silver and Intel^® Celeron^® processors that offer an unmatched balance of performance, media and collaboration for education systems.
• Intel announced a new line of 11th Gen Intel^® Core™ H-series mobile processors for gaming platforms that deliver an industry-leading balance of mobility and enthusiast-level gaming.
• Intel also previewed products coming to market later in 2021, including 11th Gen Intel^® Core™ S-series desktop processors (code-named “Rocket Lake-S”) and its next-generation processors (code-named “Alder Lake”).

 

SANTA CLARA, Calif.–(BUSINESS WIRE)–
In a world where computing is pervasive and intelligence is distributed across every surface – from the cloud to the network to the intelligent edge – Intel today at CES 2021 highlighted how it is driving technology leadership to define the future of computing for people, business and society.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210111005970/en/

To help people navigate through this extraordinary time, Intel introduced new processors for business, education, mobile and gaming computing platforms – all designed to offer the premium PC experiences people deserve, with the most choices and no limits.

More:Intel at CES 2021 (Press Kit) | Mobileye Innovation Will Bring AVs to Everyone, Everywhere (News Release) | 11th Gen Intel vPro Platform (Product Brief) | 11th Gen Intel Core H Series Processors (Product Brief) | 11th Gen Intel Core H Series Processors for Ultraportable Gaming (Press Deck)

“Only Intel has the breadth of products spanning multiple architectures; the large, open ecosystem; sheer scale of manufacturing footprint; and deep technical expertise customers need to unlock opportunities in this era of distributed intelligence,” said Intel Executive Vice President Gregory Bryant. “With an intense focus on execution for our core products and across our broader portfolio, we’re introducing a series of leadership products at CES with more following throughout the year.”

Introducing 11th Gen Intel^® Core™ vPro^®: The Best Platform for Business

For business, Intel introduced the 11th Gen Intel vPro platform, an unrivaled business platform delivering the industry’s highest performance and world’s most comprehensive hardware-based security². The new 11th Gen Intel Core vPro processors unveiled today are based on the world’s best business processor for thin-and-light laptops² and, when combined with the new Intel Core vPro platform, offer:

• Intel® Hardware Shield, providing the world’s most comprehensive security deep in hardware for business³ and the industry’s first silicon-enabled artificial intelligence (AI) threat detection to help stop ransomware and crypto-mining attacks. It is also equipped with Intel® Control Flow Enforcement Technology, ground-breaking technology to help shut down an entire class of attacks that long evaded software-only solutions⁴.
• Intel 10-nanometer (nm) SuperFin technology, delivering industry-leading performance, Intel® Iris® X^e graphics and the world’s biggest Wi-Fi improvement in 20 years – with integrated Intel® Wi-Fi 6/6E (Gig+) that enables up to six times faster uploads and downloads in the office and nearly three times faster speeds at home versus standard Wi-Fi 5⁵.
• Eight times⁶ better AI performance, enabling businesses new compute power to keep pace with the fast-changing software ecosystem, and up to 2.3 times faster⁷ creation and video editing compared to the previous generation.
• Up to 23% faster productivity⁸ than the competition when using apps like Office 365 and the best business collaboration experience, enabling more than 50% faster⁹ office productivity compared to the competition while on a video conference call.

Intel also launched the Intel® Evo™ vPro® platform, the best laptop experience for business users¹⁰. Laptop designs verified on the Intel Evo vPro platform are stylish, thin and light and provide an amazing immersive visual experience. They also offer remarkable responsiveness, instant wake and real-world battery life. More than 60 new laptops from top manufacturers will be available this year, combining the security and manageability of vPro and the amazing on-the-go experiences of Intel Evo. Additionally, Intel announced Intel Evo Chromebooks, enabling a new class of premium Chromebooks.

New Processors and Partnerships for Best Education Platform

Use of the PC as an essential education tool has accelerated greatly worldwide over the past year. To meet the growing needs of students, Intel introduced new N-series Intel^® Pentium^® Silver and Celeron^® processors with an unmatched balance of performance, media and collaboration for education systems. The processors are designed on Intel’s 10nm architecture, delivering up to 35%¹¹ better overall application performance and up to 78% better graphics performance gen on gen. This enables smooth application performance and browsing while multitasking, plus advanced camera and connectivity features for an enriched video conferencing and viewing experience.

As critical as advancing technology for meeting students’ evolving needs is putting laptops in their hands. Even with accelerated adoption, up to 30% of U.S. school children still lack internet or laptops for learning, and the pandemic has only exacerbated those requirements. During the last 15 years, Intel has invested more than $1 billion globally in education, including training for more than 15 million teachers. Last April, Intel launched the Online Learning Initiative and has provided hundreds of thousands of devices, as well as connectivity and resources, to students worldwide. Intel will continue these efforts in 2021 along with partners from inside and outside the technology industry.

New Line of 11th Gen Intel® Core™ H-series Mobile Processors for the Best Gaming Platforms

Intel launched a new line of 11th Gen Intel Core H-series mobile processors for gaming that extends the 11th Gen mobile family of products and pushes the limits of what’s possible for enthusiast-level gaming in laptops as thin as 16 millimeters. Led by the Intel® Core™ i7 Special Edition 4-core processor with up to 5 gigahertz (GHz) Turbo, these H35 processors are specifically targeted for ultraportable gaming. They feature new Gen 4 PCIE architecture for connecting to latest discrete graphics and deliver amazingly low latency and immersive game play on the go. At CES, Acer, ASUS, MSI and Vaio announced new systems powered by the 11th Gen Intel Core H35-series processor for ultraportable gaming, with more than 40 designs from top manufacturing partners launching in the first half of 2021.

For mobile enthusiasts who want desktop-caliber gaming and creation performance, Intel also announced an 8-core processor that will start shipping later this quarter. This platform is unique in the industry with features that would normally only be found in high-end desktop systems – including up to 5GHz, 20 lanes of PCIe Gen 4.0 architecture for fastest storage and discrete graphics, and Intel® Killer™ Wi-fi 6E (Gig+).

Preview of Next-Generation “Rocket Lake” and “Alder Lake” Technologies for Leadership Desktop and Mobile Platforms

Intel also demonstrated next-generation desktop technology for gamers and enthusiasts coming to market in 11th Gen Intel® Core™ S-series desktop processors (“Rocket Lake-S”). Featuring 19% gen-over-gen instructions per cycle (IPC) improvement¹² for the highest frequency cores and headlined by the Intel Core i9-11900K, these processors will bring even more performance to gamers and PC enthusiasts at launch in the first quarter of 2021.

Additionally, Intel demonstrated “Alder Lake,” the next-generation processor that represents a significant breakthrough in x86 architecture and Intel’s most power-scalable system-on-chip. Due in second half of 2021, Alder Lake will combine high-performance cores and high-efficiency cores into a single product. Alder Lake will also be Intel’s first processor built on a new, enhanced version of 10nm SuperFin and will serve as the foundation for leadership desktop and mobile processors that deliver smarter, faster and more efficient real-world computing.

About Intel

Intel (Nasdaq: INTC) is an industry leader, creating world-changing technology that enables global progress and enriches lives. Inspired by Moore’s Law, we continuously work to advance the design and manufacturing of semiconductors to help address our customers’ greatest challenges. By embedding intelligence in the cloud, network, edge and every kind of computing device, we unleash the potential of data to transform business and society for the better. To learn more about Intel’s innovations, go to newsroom.intel.com and intel.com.

¹ In thin & light Windows-based devices, based on 1) unique features and performance testing on industry benchmarks and Representative Usage Guides across 3 key usages: productivity, creation, and collaboration, comparing Intel® Core™ vPro® i7-1185G7 to AMD Ryzen 7 PRO 4750U and 2) an IOActive study (commissioned by Intel) comparing Intel® Hardware Shield security capabilities on 11th Gen Intel Core vPro processors with corresponding competitor technologies. All testing as of December 2020. Visit www.Intel.com/11thgenvpro for details. Results may vary.

² In thin & light Windows-based devices, based on unique features and performance testing (as of December 1, 2020) on industry benchmarks and Representative Usage Guides across 3 key usages: productivity, creation, and collaboration of Intel® Core™ vPro® i7-1185G7, including in comparison to AMD Ryzen 7 PRO 4750U. Visit www.Intel.com/11thgenvpro for details. Results may vary.

³ In thin & light Windows-based devices, based on unique features and testing by IOActive (commissioned by Intel; as of December 2020) comparing Intel® Hardware Shield security capabilities with corresponding technologies in an AMD Ryzen Pro 4750U-based system. Visit www.intel.com/11thgenvpro for details. Results may vary.

⁴ Intel Control-flow Enforcement Technology (CET) is designed to help protect against jump/call-oriented programming (JOP/COP) attack methods and return-oriented programming (ROP) attack methods, malware known as memory safety issues and which comprise over half of ZDI-disclosed vulnerabilities. Visit www.intel.com/11thgenvpro for details. Results may vary.

⁵ For more information about the data presented, visit www.intel.com/wifi6disclaimers.

⁶ As measured by MLPerf v0.7 Inference, Mobile Notebooks, Closed Division with Offline Scenario using OpenVINO 2021.1 Pre framework on MobileNetEdge model int8 GPU (Batch=16) on 11th Gen Intel® Core™ i7-1185G7 Processor vs highest attainable MLPerfv0.7 Inference, Mobile Notebooks, Closed Division with Offline Scenario using OpenVINO 2021.1 Pre framework on MobileNetEdge model int8 GPU (Batch=1) on 10th Gen Intel® Core™ vPro® i7-10810U processor

⁷ As measured by Video Editing workflow. 11th Gen Intel® Core™ vPro® i7-1185G7 Processor vs. 10th Gen Intel® Core™ vPro® i7-10610U Processor

⁸ As measured by Microsoft Office 365 workflow. 11th Gen Intel® Core™ vPro® i7-1185G7 Processor vs. MD Ryzen 7 PRO 4750U

⁹ As measured by Productivity and Collaboration Workflow. 11th Gen Intel® Core™ vPro® i7-1185G7 Processor vs. AMD Ryzen 7 PRO 4750U

¹⁰ In thin & light Windows-based devices, based on 1) unique features and performance testing on industry benchmarks and Representative Usage Guides across 3 key usages: productivity, creation, and collaboration, comparing Intel® Core™ vPro® i7-1185G7to AMD Ryzen 7 PRO 4750U and 2) an IOActive study (commissioned by Intel) comparing Intel® Hardware Shield security capabilities on 11th Gen Intel Core vPro processors with corresponding competitor technologies. All testing as of December 2020. Intel Evo vPro designs are co-engineered as part of Intel’s comprehensive laptop innovation program Project Athena then tested, measured, and verified against a premium specification and key experience indicators to ensure unparalleled user experiences. Visit www.Intel.com/11thgenvpro for details. Results may vary.

¹¹ Source: Intel estimates as of January 2021. Based on measurements on Intel Pentium Silver and Celeron measured on platforms with Intel® Pentium® Silver N6000 Processor, PL1=6W TDP, PL2 = 20W 4C4T, Turbo up to 3.3GHz, Motherboard: JSL RVP, Graphics: Intel® UHD Graphics 605, Memory: 2x4GB DDR4- 3200, Storage: 512GB Intel SSD 660P, OS: Windows* 10 20 H1, OS Version 19041.546, BIOS : 2385.02_140 vs. Intel® Pentium® N5030 Processor, PL1=6W TDP, PL2 = 15W 4C4T, Turbo up to 3.1GHz, Motherboard: GLK RVP, Graphics: Intel® UHD Graphics 605, Memory: 2x4GB DDR4 -2400, Storage: 256GB Intel® SSD 540s Series, OS: Windows* 10 19H1, OS Version: 10.0.19041.630 BIOS : 0064_42

¹² Source: Intel estimates as of January 2021. Based on measurements on Intel Internal reference platforms running SPEC CPU 2017 1-copy rate on 11th Gen Intel® Core™ i9-11900K vs 10th Gen Intel® Core™ i9-10900K (running each at the same fixed frequency).

Performance varies by use, configuration and other factors. Learn more at intel.com/PerformanceIndex​.

Performance results are based on testing as of dates shown in configurations and may not reflect all publicly available ​updates. See CES 2021 Claim Appendix on intel.com/PerformanceIndex for configuration details. No product or component can be absolutely secure.

Your costs and results may vary.

Intel technologies may require enabled hardware, software or service activation.

© Intel Corporation. Intel, the Intel logo and other Intel marks are trademarks of Intel Corporation or its subsidiaries. Other names and brands may be claimed as the property of others.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005970/en/

Daniel Francisco

916-377-9509

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Technology Hardware Security Consumer Electronics

MEDIA:

Logo

Photo

11th Gen Intel Core H-35 mobile processors for ultraportable gaming balance enthusiast-level gaming and mobility. Intel launched the processors at CES 2021 on Jan. 11, 2021. (Credit: Intel Corporation)

Photo

Intel Executive Vice President Gregory Bryant outlines in Intel’s CES 2021 news conference how the company is introducing new processors for business, education, mobile and gaming computing platforms – all designed to offer the premium PC experiences people deserve, with the most choices and no limits. As part of the all-virtual CES 2021, Intel makes clear that now is the time to “Go and Do Something Wonderful.” (Credit: Intel Corporation)

Photo

Intel Vice President Stephanie Hallford, who leads Business Client Platforms, unveils at CES 2021 the new 11th Gen Intel Core vPro platform and Intel Evo vPro platform, delivering the highest performance and most comprehensive hardware-based security. As part of the all-virtual CES 2021, Intel makes clear that now is the time to “Go and Do Something Wonderful.” (Credit: Intel Corporation)

Photo

At CES 2021, Intel introduces four new families of processors — from entry to premium — that include 27 new CPUs built specifically for business, six new CPUs for education, 12 high-performance mobile CPUs, and eight high-performance desktop CPUs. The result is more than 500 new designs for laptops and desktops that will come to market in 2021. As part of the all-virtual CES 2021, Intel makes clear that now is the time to “Go and Do Something Wonderful.” (Credit: Intel Corporation)

Photo

11th Gen Intel Core desktop processors (code-named “Rocket Lake-S”) will deliver increased performance and speeds. They will launch in the first quarter of 2021. (Credit: Intel Corporation)

Orion Engineered Carbons Announces Fourth Quarter 2020 Earnings Release Date and Conference Call

HOUSTON–(BUSINESS WIRE)–
Orion Engineered Carbons S.A. (NYSE: OEC), a worldwide supplier of specialty and high-performance carbon black, announced that the company will release its fourth quarter and full year 2020 results after the market closes on Thursday, February 18, 2021, to be followed by a conference call on Friday, February 19, 2021, at 8:30 a.m. (EST).

The dial-in details for the live conference call are as follow:

U.S. Toll Free:		1-877-407-4018
International:		1-201-689-8471
U.K. Toll Free:		0 800 756 3429
Germany Toll Free:		0 800 182 0040
Luxembourg Toll Free:		800 28 522
Luxembourg Local:		352 2786 0689

A replay of the conference call may be accessed by phone at the following numbers through February 26, 2021:

U.S. Toll Free:		1-844-512-2921
U.S. Toll/International:		1-412-317-6671
Conference ID:		13714486

Additionally, a live and archived webcast of the conference call will be available on the investor relations section of the Company’s website at: www.orioncarbons.com

About Orion Engineered Carbons S.A.

Orion is a worldwide supplier of carbon black. We produce a broad range of carbon blacks that include high-performance specialty gas blacks, acetylene blacks, furnace blacks, lamp blacks, thermal blacks and other carbon blacks that tint, colorize and enhance the performance of polymers, plastics, paints and coatings, inks and toners, textile fibers, adhesives and sealants, tires, and mechanical rubber goods such as automotive belts and hoses. Orion operates 14 global production sites and has approximately 1,425 employees worldwide. For more information, please visit our website www.orioncarbons.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005959/en/

Orion Engineered Carbons S.A.

Investor Relations

Wendy Wilson, +1 281-974-0155

[email protected]

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Chemicals/Plastics Automotive Automotive Manufacturing Tires & Rubber Manufacturing Textiles

MEDIA:

Logo

Pioneer Natural Resources Announces Fourth Quarter 2020 Earnings News Release Date and Conference Call

DALLAS–(BUSINESS WIRE)–Pioneer Natural Resources Company (“Pioneer”) (NYSE:PXD) today announced its fourth quarter 2020 earnings news release is scheduled to be issued after the close of trading on the New York Stock Exchange on Wednesday, February 17, 2021.

A conference call is scheduled for Thursday, February 18, 2021, at 9:00 a.m. Central Time to discuss the fourth quarter results. Instructions on how to listen to the call and view the accompanying presentation are shown below.

Internet: www.pxd.com

Select “Investors” then “Earnings & Webcasts” to listen to the discussion and view the presentation.

Telephone: Dial (800) 458-4121 confirmation code 7134307 five minutes before the call. View the presentation via Pioneer’s internet address above.

A replay of the webcast will be archived on Pioneer’s website. Alternatively, an audio replay will be available through March 15, 2021. To register and access the replay, click here and enter confirmation code 7134307.

Pioneer is a large independent oil and gas exploration and production company, headquartered in Dallas, Texas, with operations in the United States. For more information, visit Pioneer’s website at www.pxd.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005958/en/

Pioneer Natural Resources Contacts:

Investors

Neal Shah – 972-969-3900

Tom Fitter – 972-969-1821

Michael McNamara – 972-969-3592

Greg Wright – 972-969-1770

Media and Public Affairs

Tadd Owens – 972-969-5760

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Energy Natural Resources Mining/Minerals Oil/Gas

MEDIA:

Posted on January 11, 2021 4:33 pm

Ecolab Schedules Webcast and Conference Call on February 16

Ecolab Schedules Webcast and Conference Call on February 16

ST. PAUL, Minn.–(BUSINESS WIRE)–
Ecolab will host a live webcast of its fourth quarter earnings conference call to discuss 2020 fourth quarter results. A news release containing fourth quarter results is expected to be issued before market open on February 16, 2021.

Details for the public webcast are as follows:

TIME:		1:00 p.m. Eastern Time
DATE:		Tuesday, Feb. 16, 2021
DURATION:		One hour
LOCATION:		www.ecolab.com/investor
ARCHIVE:		A replay of the webcast and supplemental data will be available on Ecolab’s website.

About Ecolab

A trusted partner at nearly three million commercial customer locations, Ecolab (ECL) is the global leader in water, hygiene and infection prevention solutions and services. With annual sales of $13 billion and more than 45,000 associates, Ecolab delivers comprehensive solutions, data-driven insights and personalized service to advance food safety, maintain clean and safe environments, optimize water and energy use, and improve operational efficiencies and sustainability for customers in the food, healthcare, hospitality and industrial markets in more than 170 countries around the world. www.ecolab.com

To access the webcast, visit the Events and Presentations section of Ecolab’s Investor website at www.ecolab.com/investor and click on the webcast details.

Follow us on Twitter @ecolab, Facebook at facebook.com/ecolab, LinkedIn at Ecolab or Instagram at Ecolab Inc.

(ECL-C)

View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005937/en/

Michael Monahan

651.250.2809

Andrew Hedberg

651.250.2185

Nate Brochmann

651.250.3837

KEYWORDS: Minnesota United States North America

INDUSTRY KEYWORDS: Chemicals/Plastics Manufacturing

MEDIA:

Logo

Ares Management Corporation Schedules Earnings Release and Conference Call for the Fourth Quarter and Fiscal Year Ended December 31, 2020

LOS ANGELES–(BUSINESS WIRE)–
Ares Management Corporation announced today that it will report earnings for the fourth quarter and fiscal year ended December 31, 2020 on Thursday, February 11, 2021 prior to the opening of the New York Stock Exchange. Ares Management Corporation will hold its webcast/conference call on the same day at 12:00 p.m. ET to discuss its fourth quarter and fiscal year ended December 31, 2020 financial results.

All interested parties are invited to participate via telephone or the live webcast, which will be hosted on a webcast link located on the Home page of the Investor Resources section of our website at http://www.aresmgmt.com. Please visit the website to test your connection before the webcast. Domestic callers can access the conference call by dialing (888) 317-6003. International callers can access the conference call by dialing +1 (412) 317-6061. All callers will need to enter the Participant Elite Entry Number 6566667 followed by the # sign and reference “Ares Management Corporation” once connected with the operator. All callers are asked to dial in 10-15 minutes prior to the call so that name and company information can be collected. For interested parties, an archived replay of the call will be available through March 11, 2021 to domestic callers by dialing (877) 344-7529 and to international callers by dialing +1 (412) 317-0088. For all replays, please reference conference number 10150592. An archived replay will also be available through March 11, 2021 on a webcast link located on the Home page of the Investor Resources section of our website.

About Ares Management Corporation

Ares Management Corporation (NYSE: ARES) is a leading global alternative investment manager operating integrated groups across Credit, Private Equity, Real Estate and Strategic Initiatives. Ares Management’s investment groups collaborate to deliver innovative investment solutions and consistent and attractive investment returns for fund investors throughout market cycles. Ares Management’s global platform had approximately $179 billion of assets under management as of September 30, 2020 with more than 1,400 employees operating across North America, Europe and Asia Pacific.

Forward-Looking Statements

Statements included herein may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, which relate to future events or our future performance or financial condition. These statements are not guarantees of future performance, condition or results and involve a number of risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described from time to time in our filings with the Securities and Exchange Commission. Ares Management Corporation undertakes no duty to update any forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005906/en/

Ares Management Corporation

Carl Drake, 800-340-6597

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Logo

Quanterix Receives FDA Emergency Use Authorization for SARS-CoV-2 N Protein Antigen Test

Antigen test available on Simoa HD-X Analyzer® intended for qualitative detection of the nucleocapsid protein (N protein) from SARS-CoV-2 in nasopharyngeal swab specimens

Full suite of Research Use Only Assays Also Available for SARS-CoV-2 Acute and Long Hauler Surveillance and Profiling Studies

BILLERICA, Mass.–(BUSINESS WIRE)–Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that the Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for its Simoa® SARS-CoV-2 N Protein Antigen Test that can be run on the Simoa HD-X Analyzer®, a fully automated high-throughput immunoassay instrument.

The Simoa SARS-CoV-2 N Protein Antigen Test detects the presence of the SARS-CoV-2 virus nucleocapsid protein (or N protein) which is known to be elevated in respiratory fluids during the initial acute phase of the infection. Direct detection of antigen proteins from the virus may be a more meaningful measure of infection status than detection of RNA by rRT-PCR because genetic material can linger even after the virus has left the body, resulting in increased risk of false positives¹. In clinical studies, the test demonstrated a sensitivity of 97.7% (positive percent agreement) and specificity of 100% (negative percent agreement) up to 14 days following onset of symptoms.

Under the current EUA, the SARS-CoV-2 N Protein Antigen Test is intended for use with nasopharyngeal (NP) samples in individuals suspected of COVID-19 by their healthcare providers. Quanterix will be pursuing authorization for additional sample types, including nasal swabs, saliva, and capillary dried blood obtained from a fingerstick. Preliminary clinical research studies suggest the viral antigen may be readily detectable in asymptomatic and pre-symptomatic patients, and Quanterix is exploring extending the test to screening applications, home-based sample collection and pooling to enable larger scale testing.

FDA authorization of the Simoa SARS-CoV-2 N Protein Antigen Test for NP samples is an important early step in a project funded by the NIH Rapid Acceleration of Diagnostics (RADx) initiative to apply Simoa digital biomarker technology to decentralized SARS-CoV-2 antigen detection in non-invasive sample types. An ultimate aim of this NIH program is to improve clinical laboratory tests that will increase the capacity of SARS-CoV-2 testing in the U.S.

“As case counts and positivity rates rise globally, the COVID-19 testing landscape is of critical importance,” said Kevin Hrusovsky, Chairman, Chief Executive Officer and President, Quanterix and Founder, Powering Precision Health (PPH). “Antigen viral levels, if precisely tested, are potentially a better measure of active infection, and for understanding the kinetics and distribution of viral load across different sample types over the duration of the infection, treatment and recovery. We are pleased to announce a test that not only provides high levels of sensitivity and specificity, but is economical, well suited for high throughput testing and utilizes a complementary supply chain helping efforts to scale testing.”

Simoa RUO assays for COVID-19 Research

Quanterix offers a family of assays tailored to RUO applications. In addition to its EUA assay, Quanterix today also announced the release of the SARS-CoV-2 N Protein Antigen Advantage Assay, tailored for Research Use. This quantitative ultra-sensitive assay is directed to research applications in sample matrices including NP swabs, nasal swabs, serum, plasma, capillary dried blood, and saliva. The assay complements the quantitative Simoa SARS-CoV-2 IgG antibody assay recently introduced for the HD-X instrument which enables researchers to measure both the virus and immune response from the same samples including blood obtained by minimally invasive fingerstick collection.

“In addition to direct viral antigen and antibody detection capabilities, researchers around the world require the most sensitive and specific assays for both immune monitoring and disease profiling applications,” said Hrusovsky. “Our expanded RUO portfolio of ultrasensitive assays also includes customizable panels of up to 10 critical biomarkers for cytokine and chemokine profiling and for carefully monitoring cytokine storms. Our team is working diligently to facilitate research being done on patients with non-resolving immune responses (or COVID-19 long haulers), as well as those with associated vascular and neurological effects. Blood-based biomarkers including antigen, IgG, Nf-L, GFAP, in addition to angiogenesis panels can accurately quantify viral load, immune response, organ damage and level of inflammation from minimally invasive samples at ultra-sensitive levels.”

Simoa Technology

Simoa (single molecule array technology) is a revolutionary digital approach to immunoassays which allows single molecules to be counted for protein biomarker research applications, changing the way in which the biology of health and disease is studied by giving scientists the ability to closely examine critical biomarkers. In doing so, Quanterix enables development of methods providing much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for applications in a majority of therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease.

For more information on Quanterix’ Simoa technology, visit https://www.quanterix.com/technology. To learn more about Quanterix’ infectious disease research and RUO assay development solutions, visit https://www.quanterix.com/therapeutic-areas/infectious-disease.

About Quanterix

Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa®, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts. For additional information, please visit https://www.quanterix.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

_________________

¹https://www.medrxiv.org/content/10.1101/2020.10.02.20205708v1

View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005994/en/

Quanterix Corporation

Stephen Hrusovsky, 774-278-0496

[email protected]

PAN Communications

Staci Didner, 617-502-4300

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Medical Supplies Health FDA Infectious Diseases Other Science Research Science

MEDIA:

Logo

Certain BlackRock Closed-End Funds Announce Estimated Sources of Distributions

NEW YORK–(BUSINESS WIRE)–
Today, BlackRock Enhanced Government Fund, Inc. (NYSE: EGF) , BlackRock Debt Strategies Fund, Inc. (NYSE: DSU), BlackRock Floating Rate Income Strategies Fund, Inc. (NYSE: FRA), BlackRock Floating Rate Income Trust (NYSE: BGT), BlackRock Corporate High Yield Fund, Inc. (NYSE: HYT), BlackRock Credit Allocation Income Trust (NYSE: BTZ), BlackRock Limited Duration Income Trust (NYSE: BLW), BlackRock Core Bond Trust (NYSE: BHK), and BlackRock Multi-Sector Income Trust (NYSE: BIT) (collectively, the “Funds”) paid the following distributions per share:

Fund	Pay Date	Per Share
EGF	January 11, 2021	$0.041000
DSU	January 11, 2021	$0.060500
FRA	January 11, 2021	$0.066700
BGT	January 11, 2021	$0.064700
HYT	January 11, 2021	$0.077900
BTZ	January 11, 2021	$0.083900
BLW	January 11, 2021	$0.098100
BHK	January 11, 2021	$0.074600
BIT	January 11, 2021	$0.123700

Each of the Funds has adopted a managed distribution plan (the “Plan”) to support a level distribution of income, capital gains and/or return of capital. The fixed amounts distributed per share are subject to change at the discretion of each Fund’s Board of Directors/Trustees. Under its Plan, each Fund will distribute all available investment income to its shareholders, consistent with its primary investment objectives and as required by the Internal Revenue Code of 1986, as amended (the “Code”). If sufficient investment income is not available on a monthly basis, the Funds will distribute long-term capital gains and/or return capital to their shareholders in order to maintain a level distribution.

The Funds’ estimated sources of the distributions paid this month and for their current fiscal year are as follows:

Estimated Allocations as of January 11, 2021
Fund	Distribution	Net Investment Income	Net Realized Short- Term Gains	Net Realized Long- Term Gains		Return of Capital
EGF1	$0.041000	$0.011474 (28%)	$0 (0%)	$0 (0%)		$0.029526 (72%)
DSU1	$0.060500	$0.028500 (47%)	$0 (0%)	$0 (0%)		$0.032000 (53%)
FRA1	$0.066700	$0.031754 (48%)	$0 (0%)	$0 (0%)		$0.034946 (52%)
BGT1	$0.064700	$0.030785 (48%)	$0 (0%)	$0 (0%)		$0.033915 (52%)
HYT1	$0.077900	$0.035323 (45%)	$0 (0%)	$0 (0%)		$0.042577 (55%)
BTZ1	$0.083900	$0.036036 (43%)	$0 (0%)	$0 (0%)		$0.047864 (57%)
BLW1	$0.098100	$0.044521 (45%)	$0 (0%)	$0 (0%)		$0.053579 (55%)
BHK	$0.074600	$0.030841 (41%)	$0.043759 (59%)	$0 (0%)		$0 (0%)
BIT1	$0.123700	$0.043299 (35%)	$0 (0%)	$0 (0%)		$0.080401 (65%)

Estimated Allocations for the Fiscal Year through December 31, 2020
Fund	Distribution	Net Investment Income	Net Realized Short- Term Gains	Net Realized Long- Term Gains	Return of Capital
EGF1	$0.492000	$0.369965 (75%)	$0 (0%)	$0 (0%)	$0.122035 (25%)
DSU1	$0.832000	$0.648339 (78%)	$0 (0%)	$0 (0%)	$0.183661 (22%)
FRA1	$0.921400	$0.696324 (76%)	$0 (0%)	$0 (0%)	$0.225076 (24%)
BGT1	$0.893400	$0.678138 (76%)	$0 (0%)	$0 (0%)	$0.215262 (24%)
HYT1	$0.934800	$0.817795 (87%)	$0 (0%)	$0 (0%)	$0.117005 (13%)
BTZ1	$1.006800	$0.862348 (86%)	$0 (0%)	$0 (0%)	$0.144452 (14%)
BLW1	$1.177200	$1.017530 (86%)	$0 (0%)	$0 (0%)	$0.159670 (14%)
BHK	$0.825200	$0.755712 (92%)	$0.069488 (8%)	$0 (0%)	$0 (0%)
BIT1	$0.371100	$0.209631 (56%)	$0 (0%)	$0 (0%)	$0.161469 (44%)

¹The Fund estimates that it has distributed more than its income and net-realized capital gains in the current fiscal year; therefore, a portion of your distribution may be a return of capital. A return of capital may occur, for example, when some or all of the shareholder’s investment is paid back to the shareholder. A return of capital distribution does not necessarily reflect the Fund’s investment performance and should not be confused with ‘yield’ or ‘income’. When distributions exceed total return performance, the difference will reduce the Fund’s net asset value per share.

The amounts and sources of distributions reported are only estimates and are being provided to you pursuant to regulatory requirements and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon each Fund’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The Fund will send you a Form 1099-DIV for the calendar year that will tell you how to report these distributions for federal income tax purposes.

Fund Performance and Distribution Rate Information:
Trust	Average annual total return (in relation to NAV) for the 5-year period ending on 11/30/2020	Annualized current distribution rate expressed as a percentage of NAV as of 11/30/2020	Cumulative total return (in relation to NAV) for the fiscal year through 11/30/2020		Cumulative fiscal year distributions as a percentage of NAV as of 11/30/2020
EGF	2.50%	3.66%	2.55%		3.36%
DSU	7.04%	6.34%	0.59%		6.73%
FRA	5.36%	5.84%	0.84%		6.24%
BGT	5.27%	5.84%	0.90%		6.24%
HYT	9.52%	7.90%	7.08%		7.24%
BTZ	9.18%	6.44%	11.02%		5.90%
BLW	7.97%	7.02%	5.21%		6.44%
BHK	9.16%	5.45%	12.05%		4.57%
BIT	9.24%	8.16%	3.80%		1.36%

Shareholders should not draw any conclusions about a Fund’s investment performance from the amount of the Fund’s current distributions or from the terms of the Fund’s Plan.

BKT has adopted a Plan whereby beginning August 2018 the Fund will make fixed monthly distributions to common stockholders and will distribute all available investment income to its stockholders, consistent with its investment objective and as required by the Code. The fixed amount distributed per share is subject to change at the discretion of BKT’s Board. If sufficient investment income is not available on a monthly basis, the Fund will distribute long-term capital gains and/or return capital to its stockholders in order to maintain a level distribution. The Fund is currently not relying on any exemptive relief from Section 19(b) of the Investment Company Act of 1940, as amended (the “1940 Act”). The Fund expects that distributions under the Plan will exceed current income and capital gains and therefore will likely include a return of capital. BKT may make additional distributions from time to time, including additional capital gain distributions at the end of the taxable year, if required to meet requirements imposed by the Code and/or the 1940 Act.

BKT’s estimated sources of the distributions paid this month and for its current fiscal year are as follows:

Estimated Allocations as of January 11, 2021
Fund	Distribution	Net Investment Income	Net Realized Short-Term Gains	Net Realized Long- Term Gains		Return of Capital
BKT2	$0.034400	$0.013838 (40%)	$0 (0%)	$0 (0%)		$0.020562 (60%)

Estimated Allocations for the Fiscal Year through December 31, 2020
Fund	Distribution	Net Investment Income	Net Realized Short-Term Gains	Net Realized Long- Term Gains		Return of Capital
BKT2	$0.412800	$0.338753 (82%)	$0 (0%)	$0 (0%)		$0.074047 (18%)

²BKT estimates that it has distributed more than its income and net realized capital gains in the current fiscal year; therefore, a portion of the distribution may be a return of capital. A return of capital may occur, for example, when some or all of a stockholder’s investment is paid back to the stockholder. A return of capital distribution does not necessarily reflect BKT’s investment performance and should not be confused with ‘yield’ or ‘income’. When distributions exceed total return performance, the difference will reduce BKT’s net asset value per share.

The amounts and sources of distributions reported are only estimates and are being provided to you pursuant to regulatory requirements and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon BKT’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. BKT will send its stockholders a Form 1099-DIV for the calendar year that will illustrate how to report these distributions for federal income tax purposes.

Fund Performance and Distribution Rate Information:
Fund	Average annual total return (in relation to NAV) for the 5-year period ending on 11/30/2020	Annualized current distribution rate expressed as a percentage of NAV as of 11/30/2020	Cumulative total return (in relation to NAV) for the fiscal year through 11/30/2020	Cumulative fiscal year distributions as a percentage of NAV as of 11/30/2020
BKT	3.71%	6.62%	4.75%	6.06%

No conclusions should be drawn about BKT’s investment performance from the amount of the Fund’s distributions or from the terms of the Fund’s Plan.

The amount distributed per share under a Plan is subject to change at the discretion of the applicable Fund’s Board. Each Plan will be subject to ongoing review by the Board to determine whether the Plan should be continued, modified or terminated. The Board may amend the terms of a Plan or suspend or terminate a Plan at any time without prior notice to the Fund’s shareholders if it deems such actions to be in the best interest of the Fund or its shareholders. The amendment or termination of a Plan could have an adverse effect on the market price of the Fund’s shares.

About BlackRock

BlackRock’s purpose is to help more and more people experience financial well-being. As a fiduciary to investors and a leading provider of financial technology, our clients turn to us for the solutions they need when planning for their most important goals. As of September 30, 2020, the firm managed approximately $7.81 trillion in assets on behalf of investors worldwide. For additional information on BlackRock, please visit www.blackrock.com/corporate | Twitter: @blackrock | LinkedIn: www.linkedin.com/company/blackrock

Availability of Fund Updates

BlackRock will update performance and certain other data for the Funds on a monthly basis on its website in the “Closed-end Funds” section of www.blackrock.com as well as certain other material information as necessary from time to time. Investors and others are advised to check the website for updated performance information and the release of other material information about the Funds. This reference to BlackRock’s website is intended to allow investors public access to information regarding the Funds and does not, and is not intended to, incorporate BlackRock’s website in this release.

Forward-Looking Statements

This press release, and other statements that BlackRock or a Fund may make, may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act, with respect to a Fund’s or BlackRock’s future financial or business performance, strategies or expectations. Forward-looking statements are typically identified by words or phrases such as “trend,” “potential,” “opportunity,” “pipeline,” “believe,” “comfortable,” “expect,” “anticipate,” “current,” “intention,” “estimate,” “position,” “assume,” “outlook,” “continue,” “remain,” “maintain,” “sustain,” “seek,” “achieve,” and similar expressions, or future or conditional verbs such as “will,” “would,” “should,” “could,” “may” or similar expressions.

BlackRock cautions that forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and BlackRock assumes no duty to and does not undertake to update forward-looking statements. Actual results could differ materially from those anticipated in forward-looking statements and future results could differ materially from historical performance.

With respect to the Funds, the following factors, among others, could cause actual events to differ materially from forward-looking statements or historical performance: (1) changes and volatility in political, economic or industry conditions, the interest rate environment, foreign exchange rates or financial and capital markets, which could result in changes in demand for the Funds or in a Fund’s net asset value; (2) the relative and absolute investment performance of a Fund and its investments; (3) the impact of increased competition; (4) the unfavorable resolution of any legal proceedings; (5) the extent and timing of any distributions or share repurchases; (6) the impact, extent and timing of technological changes; (7) the impact of legislative and regulatory actions and reforms, including the Dodd-Frank Wall Street Reform and Consumer Protection Act, and regulatory, supervisory or enforcement actions of government agencies relating to a Fund or BlackRock, as applicable; (8) terrorist activities, international hostilities and natural disasters, which may adversely affect the general economy, domestic and local financial and capital markets, specific industries or BlackRock; (9) BlackRock’s ability to attract and retain highly talented professionals; (10) the impact of BlackRock electing to provide support to its products from time to time; and (11) the impact of problems at other financial institutions or the failure or negative performance of products at other financial institutions.

Annual and Semi-Annual Reports and other regulatory filings of the Funds with the Securities and Exchange Commission (“SEC”) are accessible on the SEC’s website at www.sec.govand on BlackRock’s website at www.blackrock.com, and may discuss these or other factors that affect the Funds. The information contained on BlackRock’s website is not a part of this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210111006035/en/

BlackRock Closed-End Funds

1-800-882-0052

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Posted on January 11, 2021 4:33 pm

BeiGene Announces Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab

BeiGene Announces Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab

Novartis to co-develop and commercialize tislelizumab in North America, Japan, EU, and six other European countries

BeiGene to receive $650 million upfront payment and is eligible to receive up to $1.55 billion in potential regulatory and sales milestone payments plus royalties on product sales

BeiGene has the option to co-detail tislelizumab in North America

Both parties have freedom to conduct combination trials globally

CAMBRIDGE, Mass. & BEIJING–(BUSINESS WIRE)–
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced a collaboration and license agreement with Novartis Pharma AG to develop, manufacture and commercialize BeiGene’s anti-PD-1 antibody tislelizumab in the United States, Canada, Mexico, member countries of the European Union, United Kingdom, Norway, Switzerland, Iceland, Liechtenstein, Russia, and Japan. The Companies have agreed to jointly develop tislelizumab in these licensed countries, with Novartis responsible for regulatory submissions after a transition period and for commercialization upon regulatory approvals. In addition, both companies may conduct clinical trials globally to explore combinations of tislelizumab with other cancer treatments, and BeiGene has an option to co-detail the product in North America, funded in part by Novartis.

Tislelizumab is a humanized IgG4 anti-PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages. It is approved and marketed by BeiGene in China in two indications, classical Hodgkin’s lymphoma (cHL) following at least two prior therapies and locally advanced or metastatic urothelial carcinoma (UC) with PD-L1 high expression. In addition, three supplemental new drug applications for tislelizumab have been accepted by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) and are under review. These indications are first-line treatment of patients with advanced squamous non-small cell lung cancer (NSCLC) in combination with chemotherapy, first-line treatment of patients with advanced non-squamous NSCLC in combination with chemotherapy, and previously treated unresectable hepatocellular carcinoma.

“We are excited to collaborate with Novartis to further explore the potential of tislelizumab in multiple combinations and indications. Novartis is a well-recognized leader in oncology with a unique portfolio of cancer treatments and pipeline agents,” said John V. Oyler, Co-Founder, CEO, and Chairman of BeiGene. “This important collaboration stands on a strong foundation of tislelizumab’s broad global development program, which has delivered two approvals in China, currently spans 15 potentially registration-enabling clinical trials, and has enrolled over 7,700 patients to date, including approximately 2,500 patients in more than 20 countries and regions outside of mainland China. We look forward to working with Novartis to fulfill the global opportunity of this potentially differentiated anti-PD-1 antibody.”

Under the agreement BeiGene will receive an upfront cash payment of $650 million from Novartis. BeiGene is eligible to receive up to $1.3 billion upon the achievement of regulatory milestones, $250 million upon the achievement of sales milestones, and royalties on future sales of tislelizumab in the licensed territory. Under the terms of the agreement, BeiGene will be responsible for funding ongoing clinical trials of tislelizumab, Novartis has agreed to fund new registrational, bridging, or post-marketing studies in its territory, and each party will be responsible for funding clinical trials evaluating tislelizumab in combination with its own or third party products. Each party retains the worldwide right to commercialize its propriety products in combination with tislelizumab.

Closing of the transaction is subject to the expiration or early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.

BeiGene Presentation at J.P. Morgan Healthcare Conference

The Company will present at the 39^th Annual J.P. Morgan Healthcare Conference on Thursday, January 14 at 5:20 p.m. ET.

A live webcast of the conference call can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com or http://hkexir.beigene.com. An archived replay will be available after the event for 90 days.

About Tislelizumab

Tislelizumab (BGB-A317) is a humanized IgG4 anti-PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages. In pre-clinical studies, binding to FcγR on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells. Tislelizumab is the first drug from BeiGene’s immuno-oncology biologics program and is being developed globally as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers.

Tislelizumab received conditional approval from the China NMPA as a treatment for patients with cHL who received at least two prior therapies and for patients with locally advanced or metastatic UC with PD-L1 high expression whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. Complete approval for these indications may be contingent upon results from ongoing randomized, controlled confirmatory clinical trials.

In addition, three sNDAs for tislelizumab have been accepted by the CDE of the NMPA and are under review, for first-line treatment of patients with advanced squamous NSCLC in combination with chemotherapy, for first-line treatment of patients with advanced non-squamous NSCLC in combination with chemotherapy, and for previously treated unresectable HCC.

Currently, 15 potentially registration-enabling clinical trials are being conducted in China and globally, including 13 Phase 3 trials and two pivotal Phase 2 trials.

Tislelizumab is not approved for use outside of China.

About Tislelizumab Clinical Program

Clinical trials of tislelizumab include:

• Phase 3 trial comparing tislelizumab to salvage chemotherapy in patients with relapsed/refractory classical Hodgkin Lymphoma (NCT04486391);
• Phase 3 trial in patients with locally advanced or metastatic urothelial carcinoma (NCT03967977);
• Phase 3 trial comparing tislelizumab with docetaxel in the second- or third-line setting in patients with NSCLC (NCT03358875);
• Phase 3 trial of tislelizumab in combination with chemotherapy versus chemotherapy as first-line treatment for patients with advanced squamous NSCLC (NCT03594747);
• Phase 3 trial of tislelizumab in combination with chemotherapy versus chemotherapy as first-line treatment for patients with advanced non-squamous NSCLC (NCT03663205);
• Phase 3 trial of tislelizumab in combination with platinum-based doublet chemotherapy as neoadjuvant treatment for patients with NSCLC (NCT04379635);
• Phase 3 trial of tislelizumab combined with platinum and etoposide versus placebo combined with platinum and etoposide in patients with extensive-stage small cell lung cancer (NCT04005716);
• Phase 3 trial comparing tislelizumab with sorafenib as first-line treatment for patients with hepatocellular carcinoma (HCC; NCT03412773);
• Phase 2 trial in patients with previously treated unresectable HCC (NCT03419897);
• Phase 3 trial comparing tislelizumab with chemotherapy as second-line treatment for patients with advanced esophageal squamous cell carcinoma (ESCC; NCT03430843);
• Phase 3 trial of tislelizumab in combination with chemotherapy as first-line treatment for patients with ESCC (NCT03783442);
• Phase 3 trial of tislelizumab versus placebo in combination with chemoradiotherapy in patients with localized ESCC (NCT03957590);
• Phase 3 trial of tislelizumab combined with chemotherapy versus placebo combined with chemotherapy as first-line treatment for patients with gastric cancer (NCT03777657);
• Phase 2 trial in patients with MSI-H/dMMR solid tumors (NCT03736889); and
• Phase 3 trial of tislelizumab combined with chemotherapy versus placebo combined with chemotherapy as first-line treatment in patients with nasopharyngeal cancer (NCT03924986).

About BeiGene

BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 5,000+ employees in China, the United States, Australia, Europe, and elsewhere are committed to expediting the development of a diverse pipeline of novel therapeutics. We currently market two internally discovered oncology products: BTK inhibitor BRUKINSA^® (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneUSA.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the further advancement of, and anticipated clinical development, regulatory milestones, and commercialization of tislelizumab; the parties’ commitments and the potential benefits of the collaboration, and the conditions to closing and expected timing for the closing of the transaction. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene’s ability to achieve commercial success for its marketed products and drug candidates, if approved; BeiGene’s ability to obtain and maintain protection of intellectual property for its technology and drugs; BeiGene’s reliance on third parties to conduct drug development, manufacturing and other services; BeiGene’s limited operating history and BeiGene’s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; and the impact of the COVID-19 pandemic on the Company’s clinical development, commercial and other operations, as well as those risks more fully discussed in the section entitled “Risk Factors” in BeiGene’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene’s subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210111006028/en/

Investor Contact

Craig West

+1 857-302-5189

[email protected]

Media Contact

Liza Heapes or Vivian Ni

+1 857-302-5663 or + 1 857-302-7596

[email protected]

KEYWORDS: China United States North America Asia Pacific Massachusetts

INDUSTRY KEYWORDS: Biotechnology Health Pharmaceutical Clinical Trials Oncology

MEDIA:

Logo